Carregant...
Satralizumab: First Approval
Satralizumab (Enspryng(®)), a humanized anti-interleukin-6 (IL-6) receptor monoclonal recycling antibody, has been developed by Chugai Pharmaceutical and Roche for the treatment of neuromyelitis optica spectrum disorder (NMOSD). In June 2020, based on positive results from two pivotal phase III tria...
Guardat en:
| Publicat a: | Drugs |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer International Publishing
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7522096/ https://ncbi.nlm.nih.gov/pubmed/32797372 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01380-2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|